InnoSer is teaming up with several key national and international partners to create a heart-on-a-chip devices by employing cardiac organoids that recapitulate the biology and physiology of the native human heart. Utilizing microengineering strategies allows vascularization of the cardiac organoids with conservation of cardiomyocyte anisotropy.
InnoSer develops state of the art technologies to monitor the behavior and responses of future cardiac organoids including optical and electrophysiological measuring methods. These methods will ultimately be adapted to use as high throughput screening assays to facilitate fast and reliable drug discovery and preclinical drug development for cardiovascular diseases.
Prof. Dr. Leon de Windt
Involved in InnoSer’s Scientific Advisory Board, Dr. de Windt from University Maastricht focuses on cardiac gene regulatory mechanisms by transcription factors and microRNAs that control pathological cardiac remodelling, an early step towards heart failure.